#NEWS: Our targeted cancer therapy for advanced non-small cell lung cancer (NSCLC) received Breakthrough Designation for first line use in the U.S. 🧪 Find out more here: go.boehringer.com/dz4O

#NEWS: New data available in HER2 (ERBB2)-mutant non-small cell lung cancer (NSCLC) in patients with stable, asymptomatic, and active brain metastases – underscoring our commitment to patients’ greatest needs.  🧪 Learn more about our presentation at #WCLC25: go.boehringer.com/WdAhL

We’re joining forces with @www.helmholtz-munich.de to drive new advances in fibrotic lung disease research. As leaders in fibrotic lung disease, we’re pioneering new therapies and striving towards our ultimate goal of finding a cure 🧪 Learn more: go.boehringer.com/HP-j5 #LungHealth #IPF

#NEWS for media: Our targeted cancer therapy has received approval in China for use in previously treated people with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC). 🧪 Learn more here: go.boehringer.com/YrIQ #LifeForward #Oncology

#NEWS: We are further strengthening our commitment to vision preservation by teaming up with Palatin Technologies. This partnership aims to develop a new first-in-class treatment for diabetic retinopathies. 🧪 Learn more: go.boehringer.com/py5Iu #EyeHealth #DiabeticRetinopathy #Innovation

At 37, Samantha was diagnosed with non-small cell #lungcancer (NSCLC). With support from her husband Justin and care team, she learned about #biomarker testing 🧪 to understand her cancer’s unique profile. #LifeForward #Oncology #Medsky

#NEWS for media: Our targeted cancer therapy has been approved in the U.S. for people with HER2 (ERBB2)-mutant advanced non-small cell lung cancer by the U.S. @fda.gov‬. Learn more here 👉: www.boehringer-ingelheim.com/human-health... #LifeForward #Oncology

#NEWS: With Click Therapeutics, we’re excited to announce our Phase III clinical study in people with experiential negative symptoms of schizophrenia met its primary endpoint. This is an important step forward in advancing mental health care 🧪. Learn more: go.boehringer.com/cvjNF

#NEWS: First Half of 2025 👉 EUR 14.0 billion in group net sales 👉 Zongertinib in #oncology and nerandomilast in #pulmonaryfibrosis near launch 👉 #AnimalHealth business grew by 7.6% 👉 Fast-growing pipeline in cardio-renal-metabolic diseases Learn more ➡️ go.boehringer.com/w7ce3

#NEWS: We’re kicking off a new chapter in digital health through our collaboration with Eko Health to improve heart murmur detection in dogs. We will bring an AI-powered tool to veterinarians to give dogs and pet owners more years of life to love. 🐕 #LifeForward Learn more: go.boehringer.com/4olwa

#NEWS: Tackling cardiovascular, renal and metabolic conditions together may be the key to hitting the UN’s 2030 goal of cutting early deaths from #NCDs by a third. Explore how 16 countries are tackling these challenges in the global Future Health report, launched at #WHA78. 👉 bit.ly/4jeQ6WZ

#NEWS: Pivotal FIBRONEER™-IPF and FIBRONEER™-ILD phase III full data in IPF and PPF presented at #ATS2025 and published in @nejm.org. IPF and PPF are serious conditions that can cause irreversible lung damage and continued decline in lung function. 🧪 👉 go.boehringer.com/1fG0l #LifeForward

#NEWS: We are joining forces with @tempusai.bsky.social By combining our experimental data with Tempus AI's real-world data on its AI-powered platform, we aim to pave the way for novel cancer treatments. Learn more: bit.ly/43owlqa #DataScience #Cancer #ResearchCollaboration

#NEWS: By using ViVerita's in vivo screening platform, we strive to identify higher quality targets faster, with fewer failures to accelerate the delivery of novel treatments for cancer patients with high need. 🧪

#NEWS: Together with the University of Oxford and Cumulus Neuroscience we are investigating new wearable technology. This will help gain insights into brain activity of people living with psychiatric disorders and develop new #PrecisionPsychiatry treatments. Learn more: bit.ly/4jsOIAN

#NEWS: New survey shows over 90% of animal owners trust and appreciate veterinary teams but underestimate the profession’s demands. Learn more: 👉 go.boehringer.com/o9qo Survey conducted with Kynetec. #WorldVeterinaryDay #LifeForward

Our mission is to redefine mental health care. We invest in research and forge unique partnerships to help transform lives. Though the journey is complex, we’re committed to ‘failing forward’— using every setback as a stepping stone toward progress. Learn more: bit.ly/42kZqSw #LifeForward

In our 2024 #AnnualReport Magazine titled 'Think Beyond' we reflect on our achievements and showcase some amazing stories and voices of our colleagues and other experts. Take a look at where we find our purpose, what drives us and where we strive to make a difference. ➡️ bit.ly/4cetX9m #LifeForward

#PRESS: In 2024, we 👉 invested EUR 6.2 billion in R&D 🧪 👉 helped more than 66 million patients 👉 further advanced our sustainability efforts 👉 kept working on breakthrough solutions that improve lives of humans & animals. Check it out ➡️ bit.ly/3FMzAzg

#Journalists: At our Annual #Press Conference on April 2, we'll discuss our performance and major milestones achieved in 2024 and provide an outlook for 2025 and beyond. Join us to get the latest news firsthand. Register now ➡️ bit.ly/4irOfhj

Caring for a loved one can be rewarding, but it can also take a toll on your career, relationship or health. Looking after your own wellbeing and ensuring your needs are being met are equally as important as looking after your loved ones. What are your tips for other caregivers? #SupportCaregivers

🧪#NEWS: We are looking forward to working with @saliprobiotech.bsky.social's team of scientists, to develop new medicines addressing challenging drug targets to transform patients' lives. #science #LifeForward

🧪 Meet our colleague Dr. Zeena Williams whose team ensures the quality of new compounds made for patients in clinical trials. It was her teacher who instilled her passion for chemistry. Learn how Zeena supports future women in #science: go.boehringer.com/kq2IX #LifeForward #WomenInSTEM #chemsky

#NEWS: We’ve just launched a new three-in-one poultry vaccine including protection against H5 avian influenza. While traditional bird flu vaccines often only cover one clade at a time, our new vaccine protects against the most prevalent and infectious H5 clades. Learn more: go.boehringer.com/3Vm9k

Every minute, 30 people worldwide suffer a #stroke. Our colleague Horst was one of them. His story highlights how swift action can significantly improve the chances of long-term recovery: go.boehringer.com/UHT3 #LifeForward

#NEWS: We are starting a Phase I/II trial of our potential first-in-class, inhaled gene therapy, which aims to improve outcomes in people with cystic fibrosis regardless of gene mutations. Learn more: bit.ly/3Qp52WD #CysticFibrosis #ResearchAndDevelopment #Innovation

#NEWS: Our targeted cancer therapy candidate for previously treated patients with advanced HER2 (ERBB2)-mutant non-small cell lung cancer (NSCLC) has been granted Priority Review from the @fda.gov. Learn more here: go.boehringer.com/7CFqS

Pregnant and breastfeeding individuals are one of the traditionally underrepresented groups in #ClinicalTrials. Xu Ling, our Head of Quality Medicine in China, is committed to solve this problem. Learn what breaking new ground as a #WomenInScience means to her: go.boehringer.com/100uL #LifeForward

Looking for #WomenInSTEM in history books? Our site in Ochsenhausen, Germany, has been founded by two women in 1971. Hear more from our colleague Dr. Ingrid Rapp who joined the lab in the 90s and was part of the transformation into a biotech company: go.boehringer.com/C_8j5 #LifeForward

#WomenInSTEM have been breaking new ground - yesterday, today, and tomorrow. On the 10th International Day of Women and Girls in Science, we share the stories of our colleagues Ingrid, Ling, and Zeena. See what working in science means for them: go.boehringer.com/wEaFd #LifeForward